Mersana Therapeutics Inc • MRSN

Capital at risk.

About Mersana Therapeutics Inc
Ticker
info
MRSN
Trading on
info
NASDAQ
ISIN
info
US59045L1061
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Martin H. Huber M.D.
Headquarters
info
840 Memorial Drive, Cambridge, MA, United States, 02139
Employees
info
102
Website
info
mersana.com
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$42.9M
P/E ratio
info
-
EPS
info
-$0.59
Dividend Yield
info
0.00%
Beta
info
0.82
Forward P/E ratio
info
0
EBIDTA
info
$-75.3M
Ex dividend date
info
-
Price & volume
Market cap
info
$42.9M
Average daily volume
info
3M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
1.26
Price to book
info
32.03
Earnings
EPS
info
-$0.59
EPS estimate (current quarter)
info
-$0.19
EPS estimate (next quarter)
info
-$0.20
EBITDA
info
$-75.3M
Revenues (TTM)
info
$34M
Revenues per share (TTM)
info
$0.28
Technicals
Beta
info
0.82
52-week High
info
$2.83
52-week Low
info
$0.26
50-day moving average
info
$0.35
200-day moving average
info
$1.03
Short ratio
info
4.92
Short %
info
13.20%
Management effectiveness
ROE (TTM)
info
-505.14%
ROA (TTM)
info
-30.90%
Profit margin
info
-217.63%
Gross profit margin
info
$-38.7M
Operating margin
info
-890.05%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-70.20%
Share stats
Outstanding Shares
info
125M
Float
info
93.8M
Insiders %
info
1.48%
Institutions %
info
71.49%
Analyst Insights & forecasts
info

89% Buy

11% Hold

0% Sell

Based on information from 9 analysts.

Average price target

info
$4.29
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.20
-$0.17
-17.65%
Q2 • 24Missed
-$0.09
-$0.19
51.35%
Q3 • 24Beat
-$0.11
-$0.17
34.33%
Q4 • 24Beat
-$0.19
-$0.18
-5.56%
Q1 • 25Missed
-
-$0.16
100.00%
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$16.4M
$-14.1M
-86.28%
Q4 • 24
$2.8M
$-24.1M
-875.93%
Q1 • 25
-83.17%
70.88%
915.16%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$145M
$154M
106.57%
Q4 • 24
$112M
$143M
127.45%
Q1 • 25
-22.25%
-7.03%
19.58%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-19.3M
$50M
$-1.9M
$-19.3M
Q4 • 24
$-29.3M
$27M
$-3.1M
$-29.3M
Q1 • 25
52.33%
-46.00%
68.02%
52.33%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Mersana Therapeutics Inc share?
Collapse

Mersana Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Mersana Therapeutics Inc have?
Collapse

Mersana Therapeutics Inc currently has 125M shares.

Does Mersana Therapeutics Inc pay dividends?
Collapse

No, Mersana Therapeutics Inc doesn't pay dividends.

What is Mersana Therapeutics Inc 52 week high?
Collapse

Mersana Therapeutics Inc 52 week high is $2.83.

What is Mersana Therapeutics Inc 52 week low?
Collapse

Mersana Therapeutics Inc 52 week low is $0.26.

What is the 200-day moving average of Mersana Therapeutics Inc?
Collapse

Mersana Therapeutics Inc 200-day moving average is $1.03.

Who is Mersana Therapeutics Inc CEO?
Collapse

The CEO of Mersana Therapeutics Inc is Dr. Martin H. Huber M.D..

How many employees Mersana Therapeutics Inc has?
Collapse

Mersana Therapeutics Inc has 102 employees.

What is the market cap of Mersana Therapeutics Inc?
Collapse

The market cap of Mersana Therapeutics Inc is $42.9M.

What is the P/E of Mersana Therapeutics Inc?
Collapse

The current P/E of Mersana Therapeutics Inc is null.

What is the EPS of Mersana Therapeutics Inc?
Collapse

The EPS of Mersana Therapeutics Inc is -$0.59.

What is the PEG Ratio of Mersana Therapeutics Inc?
Collapse

The PEG Ratio of Mersana Therapeutics Inc is 0.

What do analysts say about Mersana Therapeutics Inc?
Collapse

According to the analysts Mersana Therapeutics Inc is considered a buy.